Analysts Set Immatics N.V. (NASDAQ:IMTX) Target Price at $20.80

Immatics N.V. (NASDAQ:IMTX) has been assigned an average rating of “Moderate Buy” from the eight research firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $20.80.

Several equities analysts have weighed in on IMTX shares. Chardan Capital reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Immatics in a report on Tuesday, May 19th. Jefferies Financial Group assumed coverage on shares of Immatics in a research report on Monday, March 16th. They issued a “buy” rating and a $18.00 target price for the company. Wall Street Zen cut shares of Immatics from a “hold” rating to a “sell” rating in a research report on Saturday, May 2nd. Mizuho set a $25.00 target price on shares of Immatics in a research report on Thursday, February 19th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Immatics in a research report on Tuesday.

Immatics Stock Up 2.1%

Shares of Immatics stock opened at $9.06 on Friday. The stock has a market capitalization of $1.21 billion, a price-to-earnings ratio of -4.55 and a beta of 1.30. The company has a 50-day simple moving average of $10.80 and a two-hundred day simple moving average of $10.26. Immatics has a twelve month low of $5.05 and a twelve month high of $12.41.

Immatics (NASDAQ:IMTX) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.08). The company had revenue of $8.81 million during the quarter, compared to analyst estimates of $9.79 million. Immatics had a negative net margin of 572.35% and a negative return on equity of 47.36%. On average, sell-side analysts anticipate that Immatics will post -1.67 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Immatics

Several large investors have recently bought and sold shares of IMTX. Bank of America Corp DE increased its stake in shares of Immatics by 166.0% in the fourth quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock valued at $25,000 after buying an additional 2,231 shares during the period. Quarry LP acquired a new position in shares of Immatics during the fourth quarter valued at about $84,000. Insigneo Advisory Services LLC acquired a new position in shares of Immatics during the third quarter valued at about $103,000. Engineers Gate Manager LP purchased a new position in shares of Immatics during the second quarter valued at approximately $124,000. Finally, Fox Run Management L.L.C. purchased a new position in Immatics during the fourth quarter worth about $129,000. 64.41% of the stock is currently owned by institutional investors.

About Immatics

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.